Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RemeGen CoFRA:REG -4.11%46 Equity-to-Asset is 0.50 as of Dec. 2025, which is 11% below its 10-year median of 0.56. GuruFocus rates FRA:REG with a GF Score™ of 46/100 and a GF Value™ of €19.59 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,416 Biotechnology companies, RemeGen Co ranks worse than 67.44% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. RemeGen Co's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €437.6 Mil. RemeGen Co's Total Assets for the quarter that ended in Dec. 2025 was €878.8 Mil.
Therefore, RemeGen Co's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.50.
The historical rank and industry rank for RemeGen Co's Equity-to-Asset or its related term are showing as below:
FRA:REG'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.94 Med: 0.56 Max: 0.87
Current: 0.5
During the past 8 years, the highest Equity to Asset Ratio of RemeGen Co was 0.87. The lowest was -0.94. And the median was 0.56.
FRA:REG's Equity-to-Asset is ranked worse than 67.44% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs FRA:REG: 0.50
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
RemeGen Co Equity-to-Asset Related Terms
RemeGen Co Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:REG vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, RemeGen Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
RemeGen Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (FRA:REG) has a Equity-to-Asset of 0.50 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on RemeGen Co and its competitors. This is 11% below median its historical median of 0.56. According to the industry distribution chart, RemeGen Co ranks #955 out of 1416 companies in the Biotechnology industry, placing it in the top 67.4%.
Is RemeGen Co's Equity-to-Asset too high?
RemeGen Co's current Equity-to-Asset of 0.50 is 11% below median its 10-year median of 0.56. The Biotechnology industry median Equity-to-Asset is 0.68. RemeGen Co's value of 0.50 is 26.5% below this industry median. Based on the distribution chart, RemeGen Co ranks #955 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, RemeGen Co has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #955 out of 1416 companies for Equity-to-Asset. This places RemeGen Co in the lower half of its industry. The industry median Equity-to-Asset is 0.68. RemeGen Co's value of 0.50 is 26.5% below this benchmark. While the company's 10-year median is 0.56 vs. the industry median of 0.68, RemeGen Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current Equity-to-Asset of 0.50 is 26.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Equity-to-Asset is 0.50, which is 11% below median its own 10-year median of 0.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €19.59, compared to a current price of €8.35 — trading 57.4% below its estimated fair value. The current Equity-to-Asset is 0.50, which is 11% below median its 10-year median of 0.56 and 26.5% below the Biotechnology industry median of 0.68. RemeGen Co's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Equity-to-Asset is 0.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €8.35 is trading 57.4% below its estimated GF Value™ of €19.59.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
Equity-to-Asset: 0.50 (11% below median its 10-year median of 0.56)
GF Value™: €19.59 vs. price of €8.35 (57.4% below fair value)
Industry Position: 26.5% below the Biotechnology median (#955 of 1416)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
46GF Score
Get the complete analysis for FRA:REG
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
